Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16091682 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2PTGS1 | |
| SCHEMBL17290770 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2HSD11B1PTGS2PTGS1GPR119 | |
| SCHEMBL11504172 | 0.73 | KAT8 (0.42) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL13660334 | 0.69 | SMN1; SMN2 (0.43) | SMN1; SMN2HSD11B1 | |
| SCHEMBL22670497 | 0.68 | MAPT (0.64) | SMN1; SMN2PTGS1CA12CA1CA2 | |
| SCHEMBL11871125 | 0.64 | MEN1 (0.49) | SMN1; SMN2PTGS2PTGS1CA12CA1 | |
| SCHEMBL420793 | 0.63 | SMN1; SMN2 (0.62) | SMN1; SMN2PTGS1 | |
| SCHEMBL6928227 | 0.63 | SMN1; SMN2 (0.43) | SMN1; SMN2CA1CA2CA9 | |
| SCHEMBL28182477 | 0.62 | GAA (0.65) | SMN1; SMN2PTGS2PTGS1CA12CA1 | |
| SCHEMBL12807 | 0.62 | GAA (0.65) | SMN1; SMN2PTGS2PTGS1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682938-B2 | Pyrazolone derivatives as nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-3148972-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | Cardioxyl Pharmaceuticals Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015183839-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | TNNI3, PFKP, NOX5 | SMN1; SMN2 1078/4885HSD11B1 935/4885PTGS2 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.